| 1 Overall fatigue (follow‐up values) |
26 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.1 End of intervention |
26 |
2020 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.32 [‐0.47, ‐0.18] |
| 1.2 Follow‐up |
7 |
536 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.43 [‐0.60, ‐0.26] |
| 2 Overall fatigue (change values) |
13 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 2.1 End of intervention |
13 |
1289 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.30 [‐0.61, 0.00] |
| 2.2 Follow‐up |
4 |
178 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.47 [‐0.84, ‐0.11] |
| 3 FACT‐Fatigue (follow‐up values) |
7 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 End of intervention |
7 |
952 |
Mean Difference (IV, Fixed, 95% CI) |
1.14 [‐0.06, 2.35] |
| 3.2 Follow‐up |
2 |
112 |
Mean Difference (IV, Fixed, 95% CI) |
1.49 [‐1.95, 4.93] |
| 4 FACT‐Fatigue (change values) |
4 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.1 End of intervention |
4 |
925 |
Mean Difference (IV, Random, 95% CI) |
‐0.54 [‐3.23, 2.14] |
| 4.2 Follow‐up |
1 |
36 |
Mean Difference (IV, Random, 95% CI) |
1.28 [‐4.11, 6.67] |
| 5 EORTC QLQ‐C30 Fatigue scale (follow‐up values) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 End of intervention |
2 |
119 |
Mean Difference (IV, Fixed, 95% CI) |
‐6.83 [‐13.08, ‐0.58] |
| 5.2 Follow‐up |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 6 EORTC QLQ‐C30 Fatigue scale (change values) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 6.1 End of intervention |
2 |
73 |
Mean Difference (IV, Random, 95% CI) |
‐2.81 [‐14.98, 9.36] |
| 6.2 Follow‐up |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 7 Multidimensional Fatigue Symptom Inventory (follow‐up values) |
5 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 7.1 End of intervention |
5 |
366 |
Mean Difference (IV, Random, 95% CI) |
‐0.53 [‐1.35, 0.29] |
| 7.2 Follow‐up |
3 |
304 |
Mean Difference (IV, Random, 95% CI) |
‐2.04 [‐4.30, 0.23] |
| 8 Multidimensional Fatigue Symptom Inventory ‐ interference (follow‐up values) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 8.1 End of intervention |
2 |
62 |
Mean Difference (IV, Random, 95% CI) |
‐0.37 [‐1.34, 0.60] |
| 8.2 Follow‐up |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 9 Revised Piper Fatigue Scale total fatigue (follow‐up values) |
4 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 9.1 End of intervention |
4 |
187 |
Mean Difference (IV, Random, 95% CI) |
‐1.18 [‐2.38, 0.02] |
| 9.2 Follow‐up |
2 |
120 |
Mean Difference (IV, Random, 95% CI) |
‐1.15 [‐1.86, ‐0.43] |
| 10 Revised Piper Fatigue Scale total fatigue (change values) |
4 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 10.1 End of intervention |
4 |
166 |
Mean Difference (IV, Random, 95% CI) |
‐1.96 [‐2.93, 1.00] |
| 10.2 Follow‐up |
2 |
120 |
Mean Difference (IV, Random, 95% CI) |
‐1.14 [‐1.78, ‐0.49] |
| 11 Revised Piper Fatigue Scale behavioural/severity (follow‐up values) |
3 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 11.1 End of intervention |
3 |
121 |
Mean Difference (IV, Random, 95% CI) |
‐1.24 [‐2.49, 0.01] |
| 11.2 Follow‐up |
1 |
61 |
Mean Difference (IV, Random, 95% CI) |
‐1.41 [‐2.57, ‐0.25] |
| 12 Revised Piper Fatigue Scale affective/meaning (follow‐up values) |
3 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 12.1 End of intervention |
3 |
121 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.11 [‐3.03, ‐1.20] |
| 12.2 Follow‐up |
1 |
61 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.05 [‐3.21, ‐0.89] |
| 13 Revised Piper Fatigue Scale sensory (follow‐up values) |
3 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 13.1 End of intervention |
3 |
121 |
Mean Difference (IV, Random, 95% CI) |
‐0.44 [‐3.11, 2.22] |
| 13.2 Follow‐up |
1 |
61 |
Mean Difference (IV, Random, 95% CI) |
‐1.60 [‐2.65, ‐0.55] |
| 14 Revised Piper Fatigue Scale cognitive/mood (follow‐up values) |
3 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 14.1 End of intervention |
3 |
121 |
Mean Difference (IV, Random, 95% CI) |
‐0.72 [‐2.31, 0.87] |
| 14.2 Follow‐up |
1 |
61 |
Mean Difference (IV, Random, 95% CI) |
‐1.40 [‐2.50, ‐0.30] |
| 15 Schwartz Cancer Fatigue Scale (follow‐up values) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 15.1 End of intervention |
2 |
125 |
Mean Difference (IV, Random, 95% CI) |
‐2.01 [‐9.25, 5.23] |
| 15.2 Follow‐up |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 16 POMS fatigue scale (follow‐up values) |
2 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 16.1 End of intervention |
2 |
79 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.54 [1.00, ‐0.08] |
| 16.2 Follow‐up |
1 |
61 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.57 [‐1.08, ‐0.05] |
| 17 Visual analogue scale fatigue (follow‐up and change values) |
4 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 17.1 End of intervention |
4 |
148 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.51 [‐0.88, ‐0.14] |
| 17.2 Follow‐up |
1 |
22 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 18 Overall vigour/vitality (follow‐up values) |
10 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 18.1 End of intervention |
10 |
762 |
Std. Mean Difference (IV, Random, 95% CI) |
0.36 [0.21, 0.50] |
| 18.2 Follow‐up |
4 |
454 |
Std. Mean Difference (IV, Random, 95% CI) |
0.26 [0.04, 0.48] |
| 19 Overall vigour/vitality (change values) |
6 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 19.1 End of intervention |
6 |
359 |
Std. Mean Difference (IV, Random, 95% CI) |
0.23 [0.00, 0.45] |
| 19.2 Follow‐up |
2 |
233 |
Std. Mean Difference (IV, Random, 95% CI) |
0.20 [‐0.06, 0.46] |
| 20 MOS SF vitality (follow‐up values) |
6 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 20.1 End of intervention |
6 |
514 |
Mean Difference (IV, Fixed, 95% CI) |
3.08 [0.84, 5.31] |
| 20.2 Follow‐up |
2 |
306 |
Mean Difference (IV, Fixed, 95% CI) |
5.09 [0.99, 9.19] |
| 21 MOS SF vitality (change values) |
4 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 21.1 End of intervention |
4 |
212 |
Mean Difference (IV, Fixed, 95% CI) |
1.36 [‐0.52, 3.25] |
| 21.2 Follow‐up |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 22 POMS vigour scale (follow‐up values) |
4 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 22.1 End of intervention |
4 |
248 |
Std. Mean Difference (IV, Random, 95% CI) |
0.46 [0.13, 0.79] |
| 22.2 Follow‐up |
2 |
148 |
Std. Mean Difference (IV, Random, 95% CI) |
0.21 [‐0.34, 0.77] |
| 23 POMS vigour scale (change values) |
2 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 23.1 End of intervention |
2 |
147 |
Std. Mean Difference (IV, Random, 95% CI) |
0.25 [‐0.45, 0.95] |
| 23.2 Follow‐up |
2 |
233 |
Std. Mean Difference (IV, Random, 95% CI) |
0.20 [‐0.06, 0.46] |